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Summary In our study, we retrospectively evaluated the clinical features of patients
diagnosed as sarcoidosis at our center within the last 36 years and who had skin
involvement. Cutaneous involvement was observed in 170 patients (32.9%, 136
females, 34 males). The most frequent skin lesion was erythema nodosum (EN) (106
subjects, 20.5%). In addition, skin plaques and subcutaneous nodules were observed
in 22 cases (4.3%), maculopapular eruptions in 19 cases (3.7%), scar lesions in 15 cases
(2.9%), lupus pernio (LP) in 14 cases (2.7%) and psoriasiform plaques in five cases
(0.9%). Among patients with LP (64.3%) and scar lesions (40%), pulmonary
parenchymal involvement was more frequent than patients with other skin lesions.
Parenchymal involvement present in 10.4% of patients with EN was significantly less
than in patients with LP and scar lesions (P values, respectively, o0.001, 0.002).
When patients with skin involvement were compared to other sarcoidosis patients, it
was seen that the frequency of females among those with skin involvement was
significantly higher than the frequency among other sarcoidosis patients (Po0.001).
Parenchymal involvement in sarcoidosis patients without skin involvement was less
frequent than in patients with LP; however, more frequent than in patients with EN
(both P values¼ 0.002). As a conclusion, skin involvement was diagnosed in
approximately one-third of our sarcoidosis patients with a generally female
predominance. EN was the most frequent skin lesion encountered. Parenchymal
involvement was more frequent in patients with LP and scar lesions and less frequent
in patients with EN.
r 2003 Elsevier Science Ltd. All rights reserved.
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Introduction
Sarcoidosis is a multisystem disease of unknown
etiology characterized by the formation of non-
caseating granulomas in the affected organs.
Although different series report variable incidences
of skin involvement during the course of the
disease, nearly one-fourth of sarcoidosis patients
have skin involvement.1–3 Different skin lesions
associated with sarcoidosis have been reported.4,5
These lesions are divided into two as: specific skin
lesions where histologic examination shows the
typical sarcoid granulomas and nonspecific skin
lesions.3–5 Specific lesions are lupus pernio (LP),
infiltrated plaques, maculopapular eruptions, sub-
cutaneous nodules and scars. The most important
nonspecific skin lesion seen in sarcoidosis is
erythema nodosum (EN).5
In this study, we retrospectively aimed to
evaluate the general clinical and demographic
features of patients followed up as sarcoidosis at
our center who had specific and nonspecific skin
lesions. Also, we compared the features of subjects
with and without skin involvement.
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Materials and methods
Five hundred and sixteen patients (341 females,
175 males) attending the Lung Diseases Department
of Cerrahpa-sa Medical Faculty, ’Istanbul, fulfilled
clinical or radiologic or both features of sarcoidosis,
also supported by the histologic evidence of
noncaseating granulomas. Patients with clinical
and radiologic features of sarcoidosis have been
excluded if there was no histologic confirmation.
However, patients with acute disease onset with EN
and a radiograph with BHL were considered to have
sarcoidosis even though they did not have any
histologic confirmation. As a result, 170 of these
subjects (32.9%) who had skin involvement of
sarcoidosis were included into the study. Other
346 patients with sarcoidosis were taken as the
control group.
When diagnosing specific skin lesions, histologic
findings were considered. During the study period,
the patients had not been whole body screened for
skin lesions. The skin changes reported by the
patients and noted in the medical charts were
taken into account. Patients were included in this
study on the basis of clinical data typical of EN:
new-onset nodular hypodermatitis of o2 months
duration, discoloration varying from red to yellow-
brown, and localization usually on the legs. In the
presence of atypical hypodermatitis, skin biopsy
was performed to confirm EN.
The medical charts were used to obtain data
about the patients’ age, sex, disease stage accord-
ing to chest X-ray and biopsy results. According to
the classification of chest X-rays by De Remee:6
stage I, meant bilateral hilar lymphadenopathy
(BHL); stage II, BHL plus pulmonary parenchymal
infiltration; and stage III, parenchymal involvement
infiltration without BHL.
For statistical evaluation of the data, chi-square
and student’s t tests were used.
Results
Out of 516 sarcoidosis patients, 170 (32.9%)
presented with various skin manifestations and
136 of them were females and 34 were males. EN
was observed to be the most frequent skin lesion. In
all types of skin lesions, the number of female
patients outnumbered males. The distribution of
skin lesions and the demographic features of the
patients are shown in Table 1. Although the
differences were not significant, the LP group had
the highest and the subcutaneous nodule group had
the lowest mean age (Table 1).
Fifteen patients (14.1%) with EN simultaneously
had subcutaneous nodules, eight (7.5%) had macu-
lopapular rash and skin plaques, and one had LP.
One of the patients with maculopapular rash also
had a cutaneous plaque. In addition, the clinical
presentation of 71 (67%) of the 106 patients with EN
was in the form of acute sarcoidosis-L .ofgren
syndrome.
When the clinical and demographic features of
patients with skin involvement were compared to
other sarcoidosis patients, results as shown in Table
2 were obtained. The prevalence of females among
sarcoidosis patients with skin involvement was
significantly higher in comparison to those without
skin involvement (Po0.001). Although the mean
age and the frequency of pulmonary parenchymal
involvement was less in the group with skin
involvement, the difference was not significant
(Table 2).
The distribution of skin lesions in various radio-
graphic stages of sarcoidosis is shown in Table 3.
Pulmonary parenchymal involvement was most
frequent in subjects with LP (64.3%) and scar
lesions (40%) (Table 1). The incidence of parench-
ymal involvement in patients with EN was signifi-
cantly less frequent than in patients with LP,
scar lesions and those without skin involvement
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Table 1 The frequency of various skin lesions in our sarcoidosis patients, the demographic features and the
frequency of parenchymal involvement in these different groups.
n (%) Females Age Parenchymal involvement
n (%) Mean7SD Range
Erythema nodosum 106 (20.5) 86 (81.1) 41.6712.9 10–67 11 (10.4)
Skin plaques 22 (4.3) 18 (81.8) 42.4710.9 18–60 4 (18.2)
Subcutaneous nodules 22 (4.3) 18 (81.8) 39.1þ 14.8 10–63 4 (18.2)
Maculopapular rash 19 (3.7) 15 (79) 40.3þ 8.4 27–56 2 (10.5)
Scar lesions 15 (2.9) 11 (73.3) 41.1714.2 16–66 6 (40)
Lupus pernio 14 (2.7) 13 (92.8) 44.9711.4 24–67 9 (64.3)
Psoriasiform lesions 5 (0.9) 4 (80) 39.6þ 7.7 26–44 F
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(P values, respectively, o0.001, 0.002 and 0.002).
The incidence of parenchymal involvement in
patients with LP was significantly higher than in
patients with maculopapular rash, plaque lesions,
subcutaneous nodules and patients without skin
involvement (P values, respectively, 0.002, 0.01,
0.01, 0.002).
Discussion
Different series report variable frequencies of skin
involvement in sarcoidosis.3,5 In our study, approxi-
mately one-third of the patients had sarcoidosis-
related skin lesions. In two different series, skin
lesions other than EN were reported to be 11% and
19%.3,5 In our study, the frequency of skin lesions
other than EN was 18.8%. The frequency of
cutaneous involvement and also that of particular
types of skin lesions in sarcoidosis vary in different
races and geographical regions. Studies from
America reported that in addition to sarcoidosis
being more frequent in individuals of African-
American origin, skin involvement in these subjects
also took a more severe form.7,8 One study said
that black South African sarcoidosis patients had
extensive skin involvement.9 Indian sarcoidosis
patients were reported to have skin involvement
at a frequency of 42%.10 Although LP was previously
thought to be limited to Northern Europe, patients
from other areas of the world have also been
reported.9 Studies from USA, UK and Finland
reported that one of the most frequent causes of
EN was sarcoidosis.11–13
We observed that females were more frequent in
our sarcoidosis patients with skin involvement than
in those with no skin involvement. Other series
about skin involvement in sarcoidosis similarly
reported that skin was more frequently involved
in females.3,5 This might be because hormones,
particularly estrogen, might play a role in the
development of skin lesionsFespecially EN.14
Another factor which increases the frequency of
females in sarcoidosis patients with skin lesions
might be not making every patient undergo a
routine dermatologic check-up; however, including
only the skin lesions reported by the patients. This
might be explained by the possibility that females
have a greater tendency than males to observe
their body for this type of changes.
The most frequently encountered skin lesion in
our sarcoidosis patients was EN: it is known to be a
nonspecific skin lesion of sarcoidosis, points to
acute and benign disease and its frequency varies
according to geographic regions and in people of
different ethnicities.5,15 The fact that nearly two-
thirds of our patients with EN had acute sarcoidosis
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Table 3 The distribution of the various cutaneous lesions in sarcoidosis at different radiologic stages of the
disease.
n (%)
Stage 0 Stage I Stage II Stage III Stage IV
Erythema nodosum 24 (22.6) 71 (67) 9 (8.5) 2 (1.9) 0 (0)
Skin plaques 2 (9.1) 16 (72.7) 2 (9.1) 2 (9.1) 0 (0)
Subcutaneous nodules 3 (13.6) 15 (68.2) 3 (13.6) 1 (4.6) 0 (0)
Maculopapular rash 1 (5.3) 16 (84.2) 1 (5.3) 1 (5.3) 0 (0)
Scar lesions 0 (0) 9 (60) 4 (26.6) 1 (6.7) 1 (6.7)
Lupus pernio 0 (0) 5 (35.7) 7 (50) 2 (14.3) 0 (0)
Psoriasiform lesions 0 (0) 5 (100) 0 (0) 0 (0) 0 (0)
Table 2 The comparison of age, sex and radiographic stage between our sarcoidosis patients with and without
cutaneous involvement.
Cutaneous involvement No cutaneous involvement P
N % 170 (32.9) 346 (67.1) F
Female, n (%) 136 (80) 205 (59.2) o0.001
Female/Male 4 1.5
Age (mean7SD) 41.5712.6 43.9714.2 NS
Stage 0þ 1, n(%) 140 (82.4) 262 (76.3)
Parenchymal involvement, n (%) 30 (17.6) 84 (24.3) 0.09
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(L .ofgren syndrome) supports the thought that it is
associated with acute, benign disease. It was also
suggested that 17% of sarcoidosis patients pre-
sented with L .ofgren syndrome-EN.11 In different
series of EN, the etiologies are quite variable
depending on ethnic background and geographical
region; however, sarcoidosis is one of the most
frequent causes of EN.14,16 A recent large survey on
the etiology of EN reported that the most frequent
cause of secondary EN was sarcoidosis.17 In that
study, in three-fourths of the patients in whom EN
were secondary to sarcoidosis, the clinical pre-
sentation was in the form of L.ofgren syndrome.
It is known that sarcoidosis patients presenting
with EN and L .ofgren syndrome are younger and
predominantly female when compared to
others.5,18 EN, like all other types of skin lesions,
was more frequent in females. There was no
significant difference in the mean age of the groups
with different skin lesions. It was said that
sarcoidosis patients with EN had a better prognosis
than others.19,20 In our study, the prognoses of
these patients were not evaluated. However, the
less-frequent involvement of the pulmonary par-
enchyma in EN patients than in patients with other
skin lesions, and the higher number of early stage
patients among those with EN support the hypoth-
esis that EN is associated with benign disease.
Maculopapular eruptions were detected in 3.7%
of our patients. Some studies about this subject
claim that they are the most frequent form of gra-
nulomatous cutaneous involvement in sarcoidosis.21
Maculopapular lesionsFsimilar to ENFusually
accompany acute sarcoidosis and they are a good
prognostic parameter.5 In that study, pulmonary
parenchymal involvement was relatively less fre-
quent in patients with maculopapular lesions. It
was also reported that maculopapular lesions
coexist with especially EN.5 In our study, EN was
present in 42% of the subjects with maculopapular
lesions.
LP is the most characteristic skin lesion in
sarcoidosis.22 It was demonstrated that it pointed
out to chronic fibrotic disease of long duration.23 LP
was diagnosed in 2.7% of our patients. In different
series, LP was reported to occur at a frequency of
2.6% in sarcoidosis.3,5 The presence of parenchymal
involvement in more than half of our patients with
LP confirms that it is the hallmark of chronic
fibrotic disease.
Old scar infiltrations and skin plaques are
commonly observed skin lesions in generally
chronic sarcoidosis.4,24 Patients with these lesions
usually have extrathoracic involvement.2 While
these lesions were present in 2.9% of our patients,
it was important that pulmonary parenchymal
involvement was more frequent in such cases. Skin
plaques were relatively more frequent skin lesions
than scars. However, parenchymal involvement in
these cases was not as prominent as in scar lesions.
A large series reported that plaques were present in
6.2% and scar lesions in 1.3% of patients.5
It is said that subcutaneous nodules are less
frequent in sarcoidosis than other skin lesions.21
Although it was reported that subcutaneous no-
dules were associated with EN, it was also said that
they were skin lesions more frequently accompany-
ing systemic form of sarcoidosis.3,25 It was sug-
gested that they were of no prognostic impor-
tance.25 In our study, 68% of patients with
subcutaneous nodules had EN and parenchymal
involvement in these patients was less frequent
than those with chronic lesions like LP; so, we can
say that it is a benign form more commonly
associated with EN.
Of cutaneous sarcoidosis lesions, only lesions
which become chronic and leave scar, like LP and
plaque lesions, need to be treated with systemic
steroid therapy.5 However, in most of the cases
steroid therapy is needed because of organ in-
volvement other than the skin. The treatment and
overall prognosis of cutaneous sarcoidosis is pri-
marily dependent on the degree of systemic
involvement.5 In case of disfiguring skin lesions,
local or intralesional steroid therapy might some-
times be effective.26,27 It was reported that in
addition to steroids hydroxychloroquine and meth-
otrexate might be of help in chronic cutaneous
sarcoidosis.28,29 It is not generally necessary to
administer immunosuppressive therapy for EN,
symptomatic therapy is usually enough.15
Concluding, we saw that approximately one-third
of our sarcoidosis patients were affected by
different skin lesions. Females were more frequent
among subjects with skin involvement. EN was the
most common skin lesion among our sarcoidosis
patients. Although pulmonary parenchymal invol-
vement was more frequent in patients with scar
lesions and LP, it was less frequently seen in
the presence of EN, maculopapular and plaque
lesions.
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